MedDataX Logo

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

NCT ID: NCT01023100

Last Updated: 2010-06-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test the palatability of several different CP-690,550 oral preparations in trained product tester healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT00969813

Hepatic Insufficiency
COMPLETED PHASE1

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

NCT01125904

Healthy
COMPLETED PHASE1

A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form

NCT01143805

Healthy
COMPLETED PHASE1

Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers

NCT01185184

Healthy
COMPLETED PHASE1

A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

NCT06959888

Healthy Volunteer Study
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To develop a palatable pediatric oral solution dosage form of CP-690,550.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open label

Group Type EXPERIMENTAL

CP 690,550 oral solutions

Intervention Type DRUG

flavored and unflavored prototype CP-690,550 formulations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CP 690,550 oral solutions

flavored and unflavored prototype CP-690,550 formulations

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Trained healthy non-pregnant product testers, age 18-75

Exclusion Criteria

* Severe acute or chronic medical conditions, including hepatitis or tuberculosis infections or clinically significant laboratory abnormalities.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Woburn, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3921115

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
NCT04839809 COMPLETED PHASE1
Food Effect Study of CTP-543 in Healthy Volunteers
NCT03880136 COMPLETED PHASE1
Study of Celecoxib Bioavailability in Healthy Subjects
NCT00296127 COMPLETED PHASE1
A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects
NCT01184001 COMPLETED PHASE1
A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
NCT04528290 COMPLETED PHASE1
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
NCT02034773 COMPLETED PHASE1
A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects
NCT03135509 COMPLETED PHASE1
A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.
NCT06003829 COMPLETED PHASE1
A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501
NCT01549054 COMPLETED PHASE1
A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants
NCT01866007 COMPLETED PHASE1
Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men
NCT02236988 COMPLETED PHASE1
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
NCT05263895 COMPLETED PHASE1
Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers
NCT05467696 COMPLETED PHASE1
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 COMPLETED PHASE1
The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects
NCT01905553 COMPLETED PHASE1
To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers
NCT02690727 COMPLETED PHASE1
Pharmacokinetics Of Celecoxib Test Formulations
NCT00925106 COMPLETED PHASE1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
NCT05099822 TERMINATED PHASE1
Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects
NCT01053520 COMPLETED PHASE1
A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects
NCT01260155 COMPLETED PHASE1
Bioavailability Study of K0706 in Healthy Subjects
NCT03316820 COMPLETED PHASE1
A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults
NCT02666963 COMPLETED PHASE1
Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule
NCT01297595 COMPLETED PHASE1
Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532
NCT01388829 COMPLETED PHASE1
A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
NCT05515588 COMPLETED PHASE1